Japan Results Round-Up: Astellas, Daiichi Sankyo, Chugai Solid, Shionogi Hits New Heights
Eisai Revenue Slips
Executive Summary
Amid positive ongoing forex impact, Astellas, Shionogi and Daiichi Sankyo logged solid fiscal years and Chugai has good growth in its first quarter, although some of the majors are expecting a decline in sales as demand due to COVID-19 wanes. Even so, Shionogi logged record results on the back on government procurement of its pandemic antiviral.
You may also be interested in...
Biocon And Sandoz Join Hands On Japanese Humira Biosimilar
Biocon is looking to tap the global marketing clout of Sandoz by striking a deal to hand over distribution rights to its Humira (adalimumab) biosimilar in Japan.
Japan Zolbetuximab Filing Heats Up CLDN18.2 Competition
Astellas says its first approval filing globally for zolbetuximab - in Japan for gastric cancer - came faster than expected, as Scrip takes a look at the latest status of other CLDN18.2-targeting candidates in late clinical trials.
Shionogi Renews 10-Year Goal After Infectious Disease Success
Shionogi renews its 10-year strategic plan originally announced in 2020 following the successful debut of COVID-19 therapeutic Xocova. Fulfilling its 2025 goals ahead of schedule, its new strategy focuses on HIV and COVID-19 and new product launches.